Elicio Therapeutics, Inc.

NASDAQ:ELTX

Biotechnology

Healthcare
$2.70 -18.90%

-$0.89 today

Market cap
$51.48M
Beta
1.14
P/E (TTM)
-1.7
EPS (TTM)
-$2.21
52W Low $2.66High $16.00

Volume 0.41M

Average 0.34M

ELTX Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Elicio Therapeutics, Inc.NASDAQ: ELTX

Net Receivables · Q1 FY2026 · quarter ended Mar 2026

Net receivables remains negative

Q1 FY2026 net receivables was $0, compared with $0 a year earlier.

Context

  • Net receivables amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Net receivables increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Net Receivables vs competitors

How ELTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
  • Net receivables amounts to 0.0% of total assets for ELTX, versus a peer median of 0.4%.
ELTX Competitors
Net Receivables for ELTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
MISTMilestone Pharmaceuticals Inc.Mar 2026$5M USD+131.4%+42.5%2.6%
MOLNMolecular Partners AGMar 2026CHF 2.31M CHF-42.0%+3.9%2.6%
RANIRani Therapeutics Holdings, Inc.Mar 2026$2.11M USD+252.2%—4.1%
NKTXNkarta, Inc.Mar 2026$1.7M USD-29.2%+15.4%0.5%
CRDFCardiff Oncology, Inc.Mar 2026$191K USD-52.8%-38.2%0.4%
ELTXElicio Therapeutics, Inc.Mar 2026$0 USD——0.0%
PEPGPepGen Inc.Mar 2026$0 USD——0.0%
CRBPCorbus Pharmaceuticals Holdings, Inc.Mar 2026$0 USD——0.0%
ACTUActuate Therapeutics IncMar 2026$0 USD——0.0%
Peer median (excluding ELTX) —-29.2%+9.7%0.4%

Competitors are the stored peer set for ELTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents88.76M7.8M12.89M17.62M18.56M
Short-term Investments00000
Net Receivables806K0000
Inventory00000
Other Current Assets379K36K895K1.28M73K
Total Current Assets91.25M10.72M16.35M20.69M19.31M
Property, Plant & Equipment (Net)4.44M8.5M7.28M6.19M5.08M
Goodwill00000
Intangible Assets00000
Long-term Investments723K617K0696K0
Tax Assets00000
Other Non-current Assets106K2.83M3.52M600K1.47M
Total Non-current Assets5.27M11.95M10.8M7.49M6.55M
Total Assets96.51M22.66M27.15M28.18M25.86M
Account Payables4.71M2.81M4.37M1.04M672K
Short-term Debt952K692K0901K0
Tax Payables00000
Deferred Revenue2.3M1.44M01.17M0
Other Current Liabilities2.06M444K2.57M2.31M2.53M
Total Current Liabilities11.3M6.87M9.76M11.52M8.11M
Long-term Debt00020.03M9.41M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities092K11K2.83M2.62M
Total Non-current Liabilities3.71M6.88M6.02M27.97M16.12M
Total Liabilities15.01M13.75M15.77M39.49M24.23M
Common Stock300K3K96K110K178K
Retained Earnings(215.14M)(107.01M)(142.2M)(194.1M)(233.67M)
Accumulated OCI(103K)0(197K)(175K)(127K)
Other Stockholders Equity226.01M0000
Minority Interest00000
Total Equity81.51M8.92M11.37M(11.31M)1.64M
Total Debt4.66M7.48M6.92M26.04M14.51M
Net Debt(84.09M)(316K)(5.98M)8.42M(4.05M)

Elicio Therapeutics, Inc.

NASDAQ:ELTX

Intrinsic Alpha fair value

Locked

Current Price

$2.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.